Zymeworks Inc.
NASDAQ:ZYMEBiotechnology
-$0.38 today
- Market cap
- $1.81B
- Beta
- 1.14
- P/E (TTM)
- -16.6
- EPS (TTM)
- -$1.37
Volume 1.02M
Average 0.71M
ZYME Free Cash Flow
Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.
Zymeworks Inc.NASDAQ: ZYME
Free Cash Flow · Q3 FY2026 · quarter ended Sep 2026
Free cash flow dips below year-ago levels
Q3 FY2026 free cash flow of $24.11M (cash outflow) fell 24.2% year over year, behind the +69.7% change in trailing-twelve-month free cash flow. Sequentially, it fell 24.5% from the prior quarter.
Context
- Free cash flow amounted to 32.6% of revenue in FY2025, down 115.7 pp from a year earlier.
- Free cash flow increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -24.2% toward the trailing-twelve-month pace of +69.7%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Free Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (34.53M) USD
- Year-over-year change
- +69.5%
| Period | Period end | Free Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (34.53M) | +69.5% |
| FY2024 | 2024-12-31 | (113.11M) | +7.6% |
| FY2023 | 2023-12-31 | (122.38M) | -193.4% |
| FY2022 | 2022-12-31 | 130.98M | +163.7% |
| FY2021 | 2021-12-31 | (205.74M) | — |
Free Cash Flow vs competitors
How ZYME compares with its peers on the latest reported figures
- ZYME's LTM Sep 2026 free cash flow of $112.33M is the 7th largest of the 11 companies compared; the peer median is $97.39M.
- Its year-over-year change of +69.7% is the 2nd highest of 10, against a peer median of -1.0%.
- Free cash flow amounts to 42.2% of revenue for ZYME, versus a peer median of 171.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Aug 2026 | $369.81M | +253.2% | +15.3% | 52.7% | |
| LTM Sep 2026 | $259.45M | +42.8% | +26.5% | 231652.7% | |
| LTM Sep 2026 | $238.7M | +24.3% | +90.7% | — | |
| LTM Jun 2026 | $208.29M | +47.9% | +94.1% | 198.4% | |
| LTM Mar 2026 | $148.43M | -8786.2% | +15.9% | 1249.1% | |
| LTM Mar 2026 | $114.59M | -16.2% | +0.6% | 144.7% | |
| LTM Sep 2026 | $112.33M | +69.7% | — | 42.2% | |
| LTM Mar 2026 | $80.19M | -1.7% | -12.3% | 225.6% | |
| LTM Mar 2026 | $78.33M | -28.1% | -2.4% | — | |
| LTM Mar 2026 | $71.69M | -1.0% | -2.9% | 45.6% | |
| LTM Dec 2025 | $0 | — | — | 0.0% | |
| Peer median (excluding ZYME) | $97.39M | -1.0% | +15.3% | 171.6% | |
Competitors are the stored peer set for ZYME. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (211.84M) | 124.34M | (118.67M) | (122.7M) | (81.13M) |
| Depreciation & Amortization | 9.58M | 12M | 17.31M | 11.19M | 11.11M |
| Deferred Income Tax | (953K) | 1.94M | (757K) | 691K | 945K |
| Stock-Based Compensation | 10.76M | 4.02M | 8.1M | 17.79M | 28.03M |
| Change in Working Capital | 393K | 4.02M | (25.55M) | (30.95M) | 7.5M |
| Accounts Receivables | (266K) | (17.51M) | 13.92M | (36.36M) | 51.2M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 16.48M | 26.48M | (44.77M) | 14.34M | (23.65M) |
| Other Working Capital | (15.82M) | (4.96M) | 5.3M | (8.93M) | (20.05M) |
| Other Non-Cash Items | (387K) | (2.21M) | 1.27M | 13.93M | 532K |
| Operating Cash Flow | (192.45M) | 144.11M | (118.3M) | (110.04M) | (33.01M) |
| Capital Expenditures | (13.29M) | (13.13M) | (4.08M) | (3.07M) | (1.52M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (35.08M) | (40.72M) | (553.25M) | (283.74M) | (196.06M) |
| Sales of Investments | 192.96M | (40.72M) | 350.07M | 325.57M | 225.08M |
| Other Investing Activities | (881K) | 40.72M | (1.6M) | (1.08M) | 0 |
| Investing Cash Flow | 144.6M | (53.85M) | (207.25M) | 38.76M | 26.66M |
| Debt Repayment | (17K) | (14K) | (21K) | (14K) | 0 |
| Common Stock Issued | 0 | 107.53M | 76.1M | 0 | 23.32M |
| Common Stock Repurchased | 0 | 0 | 0 | (30.05M) | (41.7M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 8.03M | 1.06M | 5.77M | 9.61M | (181K) |
| Financing Cash Flow | 8.01M | 108.58M | 81.85M | (20.45M) | (18.56M) |
| Effect of Forex Changes | (325K) | 203K | 354K | 286K | (45K) |
| Net Change in Cash | (40.17M) | 199.05M | (243.36M) | (91.45M) | (24.95M) |
| Free Cash Flow | (205.74M) | 130.98M | (122.38M) | (113.11M) | (34.53M) |
Zymeworks Inc.
NASDAQ:ZYME
Intrinsic Alpha fair value
Locked
Current Price
$26.04
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.